Intra-Cellular Therapies Inc
Gesloten
SectorGezondheidszorg
0
Overzicht
Wijziging aandelenprijs
24u
Min
Max
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | -0.79% downside |
Nieuwssentiment
By Acuity
50%
50%
135 / 340 Rangschikking in Healthcare
Intra-Cellular Therapies Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Intra-Cellular Therapies Inc Prognose
Koersdoel
By TipRanks
-0.79% neerwaarts potentieel
12 Maanden Prognose
Gemiddelde 130.83 USD -0.79%
Hoogste 132 USD
Laagste 118 USD
Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Intra-Cellular Therapies Inc - Dist. in de afgelopen 3 maanden.
Sentiment
By Acuity
135 / 340 Rangschikking in Gezondheidszorg
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.